Novo Nordisk (NVO) is higher after releasing first-quarter 2026 earnings and updating its full-year outlook on Wednesday, May 6, 2026. The company said it raised its 2026 outlook due to increased expectations for GLP-1 product sales, while also detailing momentum across its obesity portfolio—particularly the Wegovy pill launch in the U.S.

For Q1 2026, the company reported net sales of DKK 96,823 million and operating profit of DKK 59,618 million, with reported sales up 32% at constant exchange rates (CER). Management said results were positively impacted by a large, non-recurring provision reversal tied to the U.S. 340B Drug Pricing Program; excluding that impact, adjusted sales fell 4% at CER and adjusted operating profit fell 6% at CER.

Novo Nordisk emphasized early traction for Wegovy pill following its U.S. launch on January 5, 2026, stating that for the week ending April 17 total weekly prescriptions exceeded 200,000 and that total prescriptions since launch surpassed 2 million. The company also pointed to multiple recent regulatory wins that broaden the portfolio, including FDA approval of Wegovy HD (injectable semaglutide 7.2 mg) and FDA approval of Awiqli, described as the first once-weekly basal insulin for type 2 diabetes.

Investors will parse management commentary on pricing pressure and realized-price declines cited in U.S. operations, as well as how quickly the newer Wegovy formulations expand the treated patient base. The company is scheduled to host an earnings call later on May 6, 2026, which may add detail on demand, supply, and how guidance assumptions translate into the remainder of 2026.